Friday 2 October 2015, Amsterdam
The report, now available on ASDReports, The report recognizes the following companies as the key players in the Global Hemophilia A Market: Baxter International, Bayer’s, CSL Behring, Novo Nordisk and Pfizer
Other Prominent Vendors in the market are: Alnylam Pharmaceuticals, Amarna Therapeutics, Asklepios, Biogen Idec, Catalyst Biosciences, Dimension Therapeutics, Dong-A Socio, Emergent BioSolutions, Grifols, Inspiration Biopharmaceuticals, Kedrion Biopharma, Octapharma, OPKO Health, rEVO Biologics, Sangamo BioSciences, Spark Therapeutics and UniQure
Commenting on the report, an analyst said: “There are new technological advancements in terms of drug manufacturing, development, and delivery. These advances has led to the development of recombinant products. For instance, animal or human plasma proteins are not used to manufacture NovoSeven, thereby decreasing the risk of infection. The use of Fc-fusion technology has increased the half-life of Eloctate in blood, thereby improving drug action.”
According to the report, the development of new hemophilia A therapeutics with prolonged action is prompting market growth. Vendors are developing a number of products, which are in the pipeline stage. The anticipated approval of these products will impact the growth of the market during the forecast period.
Further, the report states that the high cost of treatment leads to the discontinuation of therapy, thereby hampering market growth.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : email@example.com
back to News